ClinicalTrials.gg
CompletedNCT04569695Updated Mar 30, 2025

A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants

A Phase 1 interventional study of JNJ-70033093 in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the study is to characterize the pharmacokinetics of single and multiple doses of JNJ-70033093 (BMS-986177) in healthy Chinese participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy on the basis of physical examination, medical history, vital signs, (ECG), and the results of serum biochemistry, blood coagulation and hematology test and a urinalysis performed at screening. If there are abnormalities, investigator judges the abnormalities or deviations from normal to be not . This determination must be recorded in the subject's source documents and initialed by the investigator
  • Must sign an Form (ICF) indicating that they understand the purpose of, and procedures required for the study and is willing to participate in the study
  • If a woman, except for women, must have a negative highly sensitive serum (beta human chorionic gonadotropin [beta hCG]) at screening and urine (beta-hCG) pregnancy test on Day -1
  • use by men or women should be consistent with local regulations regarding the use of contraceptive methods for subject participating in clinical studies
  • Before randomization, a woman must be either not of ; of childbearing potential and practicing a highly effective method of contraception and agrees to remain on a highly effective method throughout the study and for at least 34 days after the last dose of study drug; women must have no history of excessive menstrual bleeding or hemorrhage following pregnancy delivery

Exclusion criteria

Exclusion criteria:

  • If a woman, pregnant, breast-feeding or planning to become pregnant during the study
  • Participants with current infection (confirmed by hepatitis B surface antigen [HBsAg]), or infection (confirmed by hepatitis C virus [HCV] antibody), or type-1 (HIV-1) or HIV-2 infection at study screening
  • History of, or a reason to believe a subject has a history of, drug or alcohol abuse within the past 1 year, which in the Investigator's opinion would compromise subject's safety and/or compliance with the study procedures
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) and known allergy to the study drug or any of the of the formulation
  • Preplanned surgery or procedures that would interfere with the conduct of the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort A: JNJ-70033093

    Participants will receive Dose 1 of JNJ-70033093 once daily (QD) on Day 1 followed by washout period of 4 days and then Dose 1 of JNJ-70033093 QD from Days 5 to 12.

    Drug: JNJ-70033093

  • Experimental
    Part 1: Cohort B: JNJ-70033093

    Participants will receive Dose 1 of JNJ-70033093 twice daily (BID) from Days 1 to 8.

    Drug: JNJ-70033093

  • Experimental
    Part 1: Cohort C: JNJ-70033093

    Participants will receive Dose 2 of JNJ-70033093 BID from Days 1 to 8.

    Drug: JNJ-70033093

  • Experimental
    Part 2: Cohort D: JNJ-70033093

    Participants will receive Dose 3 of JNJ-70033093 QD on Day 1 followed by washout period of 4 days and then Dose 3 of JNJ-70033093 BID from Days 5 to 12 in Cohort D. Dose escalation to Part 2: Cohort D will occur only after the safety and tolerability data of the Part 1 are assessed.

    Drug: JNJ-70033093

Interventions

  • JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.

    Also known as: BMS-986177

06

What researchers measure

Primary outcomes

  1. Cohort A and D: Plasma Concentration of JNJ-70033093 After Single Dose Administration

    Plasma concentration of JNJ-70033093 after single dose administration will be analyzed.

    Time frame: Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B)

  2. Cohort A, B, C and D: Plasma Concentration of JNJ-70033093 After Multiple Dose Administration

    Observed plasma concentration of JNJ-70033093 after multiple dose administration will be analyzed.

    Time frame: Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B)

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Number of participants who experience at least 1 occurrence of each treatment emergent adverse event (TEAE) will be assessed.

    Time frame: Up to 54 Days

  2. Number of Participants with Clinical Laboratory Abnormalities

    Number of participants with clinical laboratories (such as Hematology, Coagulation, Serum chemistry and urinalysis) abnormalities will be assessed.

    Time frame: Up to 54 Days

  3. Number of Participants with Vital Signs Abnormalities

    Number of participants with vital sign abnormalities (such as, blood pressure, pulse, respiratory rate, and temperature) will be assessed.

    Time frame: Up to 54 Days

  4. Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

    Activated partial thromboplastin time measures the time to clot formation via the intrinsic (contact) and common pathways, and is dependent on activation of contact factors (such as FXI).

    Time frame: Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B)

  5. Percentage Change From Baseline in FXI Clotting Activity

    Percentage change from baseline in FXI clotting activity will be measured using a modified aPTT assay.

    Time frame: Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B)

07

Study locations

1 site
  • West China Hospital Si Chuan University
    Chengdu, 610041, China
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Dec 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2020
First posted
Sep 30, 2020
StartActual
Mar 8, 2021
Primary completionActual
Dec 4, 2021
CompletionActual
Dec 16, 2021
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04569695
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Mar 8, 2021
Primary completion
Dec 4, 2021
Completion
Dec 16, 2021
Last update
Mar 30, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion